Acer Therapeutics announces presentation at upcoming meeting for SIMD

Acer Therapeutics announces data will be presented from a survey designed to quantify preferences of healthcare providers for Urea Cycle Disorders, UCDs, at the upcoming 44th Annual Meeting of the Society for Inherited Metabolic Disorders, SIMD, March 18th-21st in Salt Lake City, Utah. Results from the discrete choice experiment will be available on Acer‘s website following the poster presentation at SIMD on March 19 by Dr. Robert Steiner. "Quantifying Preferences for Urea Cycle Disorder Treatments Using a Discrete-Choice Experiment." This poster summarizes results from a web-based, quantitative survey study using a discrete choice experiment methodology. This study sought to capture the perspectives of healthcare providers with experience treating UCDs to quantify the attributes of nitrogen-binding medications for UCDs that may influence overall prescription and patient adherence. ACER-001 Palatability Data Presented at SIMD and GMDI 2022: Taste-Masked Coating of Sodium Phenylbutyrate Improves the Palatability of Sodium Phenylbutyrate for Treatment of Urea Cycle Disorder. Results from two Phase 1, open-label, repeated measures, taste assessment studies of ACER-001 suspension and sodium phenylbutyrate powder were presented at the SIMD Annual Meeting and Genetic Metabolic Dieticians International Conference in April 2022 and May 2022, respectively. ACER-001 for the treatment of UCDs is now marketed in the U.S. as OLPRUVA following FDA approval in December 2022. OLPRUVA Program Update: Acer also provided an update on its commercial launch activities for OLPRUVA in advance of the SIMD Annual Meeting. To support the launch of OLPRUVA(TM) in Q2 2023, the company is actively adding resources to establish its commercial and medical affairs presence in the U.S. As a part of its OLPRUVA commercialization strategy, Acer has recently introduced its patient support service, OLPRUVA Navigator by Acer Therapeutics, that is designed to assist UCD patients with support, access, education, and patient adherence to treatment. Representatives will begin accepting prescriptions in late Q2 2023. Acer is also actively engaged in negotiations regarding access for OLPRUVA(TM) with the major commercial payers and state Medicaid organizations.